The need for new treatments of neurological diseases is growing with the increasing lifespan of the human population. Typically, therapeutic drugs are administered orally or by intravenous injection. However, the passage of blood solutes into the brain is tightly regulated by the blood-brain barrier (BBB). Only molecules of relatively small size enter the human brain by simple and passive diffusion or via membrane transport proteins. As a result, many potentially useful therapeutic agents are clinically ineffective because they cannot cross the BBB.
The aim of the Lundbeck Foundation Research Initiative on Brain Barriers and Drug Delivery (RIBBDD) is to provide new tools for drug delivery across the BBB. Our multidisciplinary research program combines research on drug transport systems with research on BBB function and the neurovascular unit, the cells most closely associated with the brain endothelium.
Our vision is to provide high quality research that will help patients with neurological disorders live a better life.
Welcome to WP6
Sep 27, 2018
RIBBDD has the pleasure of welcoming professor Kristian Strømgaard and his group...
Sep 26, 2018
The RIBBDD network just received the wonderful news that...
9th RIBBDD biannual meeting
Jul 03, 2018
On May 17-18th, participants from the RIBBDD network met for the 9th biannual RIBBDD meeting...
New professor in the RIBBDD initiative
May 02, 2018
Birger Brodin has been appointed professor...
PhD defense: Sofie Hørlyck
Dec 11, 2017
Sofie Hørlyck will defend her PhD thesis...